<DOC>
	<DOCNO>NCT01167699</DOCNO>
	<brief_summary>The main objective study evaluate patient preference pain treatment respect quality life patient moderate severe non malignant pain . Patients insufficient pain relief and/or unacceptable side effect previous analgesic treatment WHO step 1 2 require around-the-clock opioid therapy include study . The WHO step I II analgesic compare new study medication OXN ( oxycodone/naloxone ) .</brief_summary>
	<brief_title>Oxycodone/Naloxone ( OXN ) Combination Moderate Severe Non-malignant Pain</brief_title>
	<detailed_description>Patients receive OXN 3 week first phase ( core phase ) second phase ( extension phase ) receive OXN daily clinical practice reimbursement OXN Netherlands Belgium discontinuation request patient .</detailed_description>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>1 . Male female patient least 18 year old moderate severe nonmalignant pain willing provide write informed consent . 2 . Females less one year postmenopausal must negative urine pregnancy test record screen visit , nonlactating , willing use adequate reliable contraception throughout study . Highly effective method birth control define result low failure rate ( i.e . le 1 % per year ) use consistently correctly sterilisation , implant , injectables , combine oral contraceptive , IUDs ( Intrauterine Device , hormonal ) , sexual abstinence vasectomise partner . 3 . Patients document history moderate severe , nonmalignant pain treat WHO step I II analgesic insufficient pain relief and/or unacceptable side effect require aroundtheclock opioid therapy ( start dose oxycodone 20 mg/day ) likely benefit WHO step III opioid therapy duration study . Patients must willing discontinue current analgesic , like opioids . Coanalgesics , antidepressant antiepileptic , continue provide coanalgesics use stable dose study . 4 . Patients willing discontinue pre study laxative medication . 5 . Patients take daily fibre supplementation bulk agent eligible maintain stable dose regimen throughout study , investigator opinion willing able maintain adequate hydration . 6 . Patients willing able participate aspect study , include use medication , completion subjective evaluation , attend schedule clinic visit , complete telephone contact , compliance protocol requirement evidence provide write , informed consent . 1 . Any history hypersensitivity oxycodone , naloxone , related product , ingredient . 2 . Patients require dose 20 mg/day oxycodone start study . 3 . Active alcohol drug abuse and/or history opioid abuse . 4 . Evidence clinically significant cardiovascular , renal , hepatic , psychiatric disease , determine medical history , clinical laboratory test , ECG result , physical examination , would place patient risk upon exposure study medication may confound analysis and/or interpretation study result . 5 . In investigator 's opinion , patient receive hypnotic central nervous system ( CNS ) depressant may pose risk additional CNS depression opioid study medication . 6 . Patients receive opioid substitution therapy opioid addiction ( e.g. , methadone buprenorphine ) . 7 . Patients uncontrolled seizure convulsive disorder . 8 . Patients confirm diagnosis ongoing irritable bowel syndrome . 9 . Patients evidence clinically significant gastrointestinal disease ( e.g . paralytic ileus , peritoneal carcinosis ) , significant structural abnormality gastrointestinal tract ( e.g . scarring , obstruction etc ) . 10 . Patients participate clinical research study involve new chemical entity experimental drug within 30 day study entry . 11 . Surgery complete prior start study , plan surgery study would influence pain bowel function study preclude completion study . 12 . Patients presently take , take , naloxone &lt; 30 day prior start study . 13 . Patients suffer diarrhoea and/or opioid withdrawal . 14 . Patients situation opioids contraindicate , severe respiratory depression hypoxia and/or hypercapnia , severe obstructive pulmonary disease , cor pulmonale , severe bronchial asthma , paralytic ileus . 15 . Patients myxodema , hypothyroidism , Addisons disease , increase intracranial pressure and/or epilepsy ( see also exclusion criterion 7 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Oxycodone/naloxone</keyword>
	<keyword>patient preference</keyword>
	<keyword>WHO step I/II</keyword>
	<keyword>Moderate severe non-malignant pain</keyword>
</DOC>